Document is current
Any future updates will be listed below
-
Authors
Cramer, Sophie H.M.
Danad, Ibrahim
Knaapen, Paul
Nurmohamed, Nick S.
Choi, Andrew D.
- License Information
-
More Information
Article History
Received: 9 December 2025
Accepted: 11 March 2026
First Online: 27 March 2026
Declarations
:
: No animal or human subjects by the authors were used in this study.
: Dr. Nurmohamed reports grants from the Dutch Heart Foundation (Dekker 03-007-2023-0068), European Atherosclerosis Society (2023), research funding/speaker fees from Cleerly, Daiichi Sankyo, Novartis and Ultragenyx, and is co-founder of Lipid Tools. Dr. Danad has research a research grant from Cleerly, Inc. and is a member of the Cleerly Scientific Advisory Board. Dr. Knaapen has received research grants from Cleerly, Inc. and HeartFlow. Dr. Choi reports consulting with Cleerly, Inc and Amgen as well as equity in Cleerly, Inc. The other authors report no disclosures.
